 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Hospital Pharmacist, Centre Régional de Pharmacovigilance, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
Clinical Pharmacologist, Centre Régional de Pharmacovigilance, Centre Hospitalier Universitaire de Grenoble
Clinical Specialist, Service de Génétique, Centre Hospitalier Universitaire de Grenoble
Reprints: Michel P Mallaret MD, Centre Régional de Pharmacovigilance, Centre Hospitalier Universitaire de Grenoble, BP 217, 38043 Grenoble Cedex 9, France, FAX (33) 04 76 76 56 55, E-mail MMallaret{at}chu-grenoble.fr
OBJECTIVE: To report a case of gastroschisis in a newborn secondary to carbimazole exposure in utero.
CASE SUMMARY: A 25-year-old white woman was treated for Graves disease with carbimazole throughout pregnancy. A boy was born prematurely by vaginal delivery, with a gastroschisis without associated malformative syndrome. Death occurred in the 25th hour of life after surgical repair.
DISCUSSION: Carbimazole is completely metabolized to methimazole after absorption. Carbimazole or methimazole intake during pregnancy has been associated with an increased incidence of scalp aplasia. Abdominal wall defects secondary to carbimazole or methimazole exposure in utero seem to be a rare occurrence. However, other cases of abdominal wall defects have been reported in 4 newborns, 2 of them associated with scalp aplasia. An objective causality assessment revealed that the relationship between the gastroschisis and the exposure to carbimazole in utero was possible.
CONCLUSIONS: It is important to emphasize the possible risk of abdominal wall defects in newborns to pregnant women taking carbimazole or methimazole.
Key Words: carbimazole, gastroschisis, hyperthyroidism, methimazole
 |
 |
 |
 |
 |
 |
 |
